COHERUS ONCOLOGY INC (CHRS) Stock Analyst Ratings
USA - NASDAQ:CHRS - US19249H1032 - Common Stock
1.425 USD
-0.15 (-9.24%)
ChartMill assigns a Buy % Consensus number of 82% to CHRS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 5.78. This target is 305.62% above the current price.
CHRS was analyzed by 11 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about CHRS.
In the previous month the buy percentage consensus was at a similar level.
CHRS was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-09-04 | Maxim Group | Upgrade | Hold -> Buy |
| 2025-04-29 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-04-24 | UBS | Maintains | Neutral -> Neutral |
| 2025-03-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-05 | Baird | Maintains | Outperform -> Outperform |
| 2024-12-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-08 | Baird | Maintains | Outperform -> Outperform |
| 2024-11-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-16 | UBS | Downgrade | Buy -> Neutral |
| 2024-08-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-01 | Baird | Maintains | Outperform -> Outperform |
| 2024-05-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-13 | Truist Securities | Maintains | Buy -> Buy |
| 2024-05-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-20 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-01-23 | Truist Securities | Maintains | Buy -> Buy |
| 2024-01-23 | Baird | Maintains | Outperform -> Outperform |
| 2023-12-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-12-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-11-28 | Truist Securities | Reiterate | Buy -> Buy |
| 2023-11-17 | Baird | Initiate | Outperform |
| 2023-11-08 | Maxim Group | Downgrade | Buy -> Hold |
| 2023-11-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-10-23 | Barclays | Maintains | Overweight -> Overweight |
| 2023-09-26 | Truist Securities | Reiterate | Buy -> Buy |
| 2023-09-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
COHERUS ONCOLOGY INC / CHRS FAQ
What is the average price target for COHERUS ONCOLOGY INC (CHRS) stock?
11 analysts have analysed CHRS and the average price target is 5.78 USD. This implies a price increase of 305.62% is expected in the next year compared to the current price of 1.425.
How do analysts rate COHERUS ONCOLOGY INC (CHRS)?
The consensus rating for COHERUS ONCOLOGY INC (CHRS) is 81.8182 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover COHERUS ONCOLOGY INC (CHRS) stock?
The number of analysts covering COHERUS ONCOLOGY INC (CHRS) is 11.